Results 31 to 40 of about 17,033 (261)

Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype

Case Reports in Gastroenterology, 2015
Direct-acting antivirals with or without peginterferon α (PEG-IFN α) plus ribavirin are now available for the treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals are potent inhibitors of HCV replication, but some of them occasionally
Tatsuo Kanda, Masato Nakamura, Reina Sasaki, Shin Yasui, Shingo Nakamoto, Yuki Haga, Xia Jiang, Shuang Wu, Akinobu Tawada, Makoto Arai, Fumio Imazeki, Osamu Yokosuka   +11 more
doaj   +1 more source

Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT

Efficacy and Mechanism Evaluation, 2021
Background: High cure rates with licensed durations of therapy for chronic hepatitis C virus suggest that many patients are overtreated. New strategies in individuals who find it challenging to adhere to standard treatment courses could significantly ...
Graham S Cooke, Sarah Pett, Leanne McCabe, Christopher Jones, Richard Gilson, Sumita Verma, Stephen D Ryder, Jane D Collier, Stephen T Barclay, Aftab Ala, Sanjay Bhagani, Mark Nelson, Chin Lye Ch’Ng, Benjamin Stone, Martin Wiselka, Daniel Forton, Stuart McPherson, Rachel Halford, Dung Nguyen, David Smith, M Azim Ansari, Helen Ainscough, Emily Dennis, Fleur Hudson, Eleanor J Barnes, Ann Sarah Walker, the STOP-HCV trial team   +26 more
doaj   +1 more source

Efficacy of direct-acting antivirals in patients with hepatitis C virus-associated cryoglobulinemic vasculitis: Results of a long-term follow-up

Научно-практическая ревматология, 2023
Objective – to evaluate the long-term outcomes of HCV eradication with direct-acting antivirals (DAAs) in patients with hepatitis C-associated cryoglobulinemic vasculitis (HCV-CV)Materials and methods.
S. V. Gavrisheva, D. T. Abdurakhmanov, N. M. Bulanov, E. L. Tanashhuk, T. P. Rozina, E. N. Nikulkina, S. Yu. Milovanova, E. A. Nabatchikova, A. L. Filatova, E. E. Starostina, T. N. Krasnova, S. V. Moiseev   +11 more
doaj   +1 more source

Mortality associated with the treatment of HCV with direct-acting antivirals [PDF]

Gut, 2017
We read with interest the study by Welzel et al 1 confirming the high efficacy of oral direct-acting antiviral agents (DAAs) for the treatment of chronic HCV infection.2 Results about safety are less clear, since in these patients who have a high risk of hepatic decompensation or death within 12 months, the rate of death was 7.8% during treatment and ...
Anne, Laurain, Laura, Kramer, Philippe, Sultanik, Anaïs, Vallet-Pichard, Philippe, Sogni, Stanislas, Pol   +5 more
openaire   +2 more sources

Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients

Annals of Hepatology, 2017
Introduction: Many of the 300,000 HCV-infected Canadians live in under-served and remote areas without access to HCV healthcare specialists. Telemedicine (TM) and advances in HCV management can facilitate linkage of these marginalized patients to ...
Curtis L. Cooper, Holly Hatashita, Daniel J. Corsi, Parmvir Parmar, Raymond Corrin, Gary Garber   +5 more
doaj   +1 more source

Update on hepatitis C: Direct-acting antivirals

World Journal of Hepatology, 2015
Hepatitis C virus (HCV) was discovered 26 years ago. For decades, interferon-based therapy has been the mainstay of treatment for HCV. Recently, several direct-acting antivirals (DAAs) have been approved for treatment of HCV-infected patients and to help combat the virus.
Leon L, Seifert, Ryan B, Perumpail, Aijaz, Ahmed   +2 more
openaire   +2 more sources

Evidence‐Based Clinical Practice Guidelines for the Management of Pediatric Febrile Neutropenia: Resource‐Sensitive Recommendations for the Asian Continent

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Febrile neutropenia (FN) is a frequent and serious complication in children receiving cancer therapy. Standardizing FN management across Asia is challenging due to variable healthcare infrastructure, diagnostic capacity, and infection patterns; however, it could improve resource use and patient outcomes.
Joliza Patricia Cañeba, Shweta Bansal, Tea Reljic, Allyne Montecillo‐Aguelo, Hamidah Alias, Farrah Amaranto, Maria Stella Aquino‐Calingasan, Bambang Ardianto, Eggi Arguni, Sally Blair, Thi Tam Dang, Maria Beatriz Gepte, Samanmalee Gunasekara, Andini Handayani, Miriam Kimpo, Catherine G. Lam, Nawachai Lertvivatpong, Sergio Licona, Ana Loseo, Ratha Mlis, Vivian Moreno Berrio, Nguyen Hoai Anh, Anna Lisa Ong‐Lim, Ha Thu Pham, Krishna Sagar Sharma, Bun Sereyleak, Sally Jane G. Velasco‐Aro, Su Yadana, Ambuj Kumar, Sheena Mukkada   +29 more
wiley   +1 more source

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy [PDF]

Clinical and Molecular Hepatology, 2020
The treatment of chronic hepatitis C (CHC) has been revolutionized in an era of all-oral direct-acting antivirals (DAAs) since 2014. Satisfactory treatment efficacy and tolerability can be provided by novel DAAs.
Chung-Feng Huang, Ming-Lung Yu
doaj   +1 more source

Diversity and complexity in neural organoids

FEBS Letters, EarlyView.
Neural organoid research aims to expand genetic diversity on one side and increase tissue complexity on the other. Chimeroids integrate multiple donor genomes within single organoids. Self‐organising multi‐identity organoids, exogenous cell seeding, or enforced assembly of region‐specific organoids contribute to tissue complexity.
Ilaria Chiaradia, Madeline A. Lancaster
wiley   +1 more source

The ‘Viennese epidemic’ of acute HCV in the era of direct-acting antivirals

Journal of Hepatology, 2022
AbstractThe recently reported epidemic of acute hepatitis C virus (HCV) infections —observed predominantly among men who have sex with men (MSM)—may now decline due to wide availability of direct‐acting antivirals (DAAs). This study aimed to investigate the current trends of acute hepatitis C in Vienna.
David Chromy, David J. M. Bauer, Benedikt Simbrunner, Matthias Jachs, Lukas Hartl, Philipp Schwabl, Caroline Schwarz, Armin Rieger, Katharina Grabmeier‐Pfistershammer, Michael Trauner, Peter Ferenci, Mattias Mandorfer, Michael Gschwantler, Thomas Reiberger   +13 more
openaire   +2 more sources